Granite Point Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,100,000
Closed -$2.31M 223
2020
Q3
$2.31M Buy
+1,100,000
New +$3.71M 0.13% 85
2018
Q4
Sell
-567,895
Closed -$2.75M 140
2018
Q3
$2.75M Hold
567,895
0.18% 50
2018
Q2
$3.41M Hold
567,895
0.31% 35
2018
Q1
$5.03M Hold
567,895
0.49% 15
2017
Q4
$4.12M Hold
567,895
0.4% 14
2017
Q3
$3.92M Sell
567,895
-1
-0% -$7 0.83% 11
2017
Q2
$4.06M Sell
567,896
-27,133
-5% -$125K 1% 14
2017
Q1
$2.83M Sell
595,029
-11,578
-2% -$35.5K 0.84% 21
2016
Q4
$1.46M Sell
606,607
-98,874
-14% -$403K 1.16% 29
2016
Q3
$3.68M Buy
705,481
+1
+0% +$5 1.44% 16
2016
Q2
$2.81M Buy
+705,480
New +$3.33M 1.2% 15
2015
Q4
$2.68M Buy
+388,945
New +$2.79M 0.4% 16

Other funds holding SBBP

Granite Point Capital Management's SBBP Position: Q4 2020 in Review

Granite Point Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2020, closing a stake of 1,100,000 shares — an estimated $2.31M sold.

Granite Point Capital Management first reported a position in SBBP in Q4 2015 and held it in 12 quarters. The position peaked at $5.03M in Q1 2018. 71 funds tracked by Wall St. Rank hold SBBP as of Q4 2020.

  • Granite Point Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q4 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 1,100,000 Strongbridge Biopharma plc. shares in Q4 2020, an estimated $2.31M.
  • Granite Point Capital Management first reported a position in Strongbridge Biopharma plc. in Q4 2015 and held it in 12 quarters.
  • Granite Point Capital Management's Strongbridge Biopharma plc. position peaked at $5.03M in Q1 2018.
  • 71 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2020.

Based on Granite Point Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.